Replimune Group, Inc.
$9.70 -$0.76 (-7.27%) 1D After hours
Replimune Group, Inc.
Key Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 24
Offering paper hit the record (Form S-3).
S-3/A - Replimune Group, Inc. (0001737953) (Filer)
RECEIPT: SEC FORM S-3, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
May 29
The stock moved +85.7% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 29 -
Apr 13
From its Feb 20 high, the share price fell 80%.
Peak close $8.64 on Feb 20; trough close $1.70 on Apr 13. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -80% -
Apr 13
The stock moved -64.3% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Apr 13
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Replimune Group, Inc.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.